सिंकोम फॉर्म्युलेशन ( इंडिया) शेयर प्राईस

सिंकॉम फॉर्म्युलेशन ( भारत) इन्व्हेस्टमेंट रेटिंग

• मास्टर रेटिंग:

• सिन्कोम फॉर्म्युलेशन लि. टॅबलेट, कॅप्सूल्स, सिरप आणि ऑइंटमेंटसह फार्मास्युटिकल प्रॉडक्ट्सची निर्मिती करते. देशांतर्गत आणि आंतरराष्ट्रीय दोन्ही बाजारात सेवा देणारे, हे अँटीबायोटिक्स, पेन रिलीफ आणि व्हिटॅमिनसारख्या उपचारात्मक विभागांमध्ये परवडणाऱ्या, उच्च दर्जाच्या औषधांची विस्तृत श्रेणी ऑफर करते.

  Syncom Formulations India has an operating revenue of Rs. 290.81 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 13% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 33% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

  डिस्कलेमर: हा स्टॉक विश्लेषण रिपोर्ट केवळ माहितीपूर्ण हेतूंसाठी अल्गोरिदमली तयार केला जातो आणि खरेदी किंवा विक्री शिफारस म्हणून विचारात घेतला जाऊ नये.